Molecular and cellular basis for designing gene vaccines against inflammatory autoimmune disease

Trends in Molecular Medicine

Volumn 9, Issue 8, 2003, Pages 331-338

  Ghoreschi, Kamran ^a   Röcken, Martin ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; VACCINE;

AUTOIMMUNE DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATORY DISEASE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; PHENOTYPE; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

EID: 0041926322     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(03)00134-5     Document Type: Article

References (76)

1. Ghoreschi, K. et al. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J. Mol. Med. (in press)
2. Granstein, R.D. (2001) New treatments for psoriasis. N. Engl. J. Med. 345, 284-287
3. Abbas, A.K. et al. (1996) Functional diversity of helper T lymphocytes. Nature 383, 787-793
4. + T cells toward a Th1 or Th2 functional phenotype. J. Immunol. 148, 47-54
5. Murphy, K.M. and Reiner, S.L. (2002) The lineage decisions of helper T cells. Nat. Rev. Immunol. 2, 933-944
6. Szabo, S.J. et al. (1997) Regulation of the interleukin (IL)-12R β2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 185, 817-824
7. Zheng, W. and Flavell, R.A. (1997) The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89, 587-596
8. Kurata, H. et al. (1999) Ectopic expression of activated Stat6 induces the expression of Th2-specific cytokines and transcription factors in developing Th1 cells. Immunity 11, 677-688
9. Ouyang, W. et al. (2000) Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 12, 27-37
10. + T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368
11. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588-594
12. Egeter, O. et al. (2000) Eradication of disseminated lymphomas with CpG-DNA-activated T helper type 1 cells from nontransgenic mice. Cancer Res. 60, 1515-1520
13. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16, 34-38
14. Rocken, M. et al. (1996) IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today 17, 225-231
15. Urban, J.F.J. et al. (1992) The importance of Th2 cytokines in protective immunity to nematodes. Immunol. Rev. 127, 205-220
16. Else, K.J. et al. (1994) Cytokine-mediated regulation of chronic intestinal helminth infection. J. Exp. Med. 179, 347-351
17. Racke, M.K. et al. (1994) Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180, 1961-1966
18. Biedermann, T. et al. (2001) Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. Eur. J. Immunol. 31, 1582-1591
19. Sadovnick, A.D. et al. (1993) A population-based study of multiple sclerosis in twins: update. Ann. Neurol. 33, 281-285
20. Olmos, P. et al. (1988) The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins. Diabetologia 31, 747-750
21. Anonymous, (1997) An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. The Finnish-German APECED consortium. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Nat. Genet. 17, 399-403
22. + T cell responses: the alternative approaches. Annu. Rev. Immunol. 15, 297-322
23. Gallucci, S. et al. (1999) Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249-1255
24. Rocken, M. et al. (1992) Infection breaks T-cell tolerance. Nature 359, 79-82
25. Bernasconi, N.L. et al. (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202
26. de Jong, E.C. et al. (2002) Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J. Immunol. 168, 1704-1709
27. Hilkens, C.M. et al. (1997) Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90, 1920-1926
28. Sparwasser, T. et al. (1998) Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28, 2045-2054
29. Hemmi, H. et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745
30. Sigmundsdottir, H. et al. (1997) Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand. J. Immunol. 45, 688-697
31. Prinz, J.C. (2001) Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin. Exp. Dermatol. 26, 326-332
32. Wucherpfennig, K.W. and Strominger, J.L. (1995) Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695-705
33. Gran, B. et al. (1999) Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Ann. Neurol. 45, 559-567
34. Atkinson, M.A. et al. (1994) Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J. Clin. Invest. 94, 2125-2129
35. Endl, J. et al. (1997) Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J. Clin. Invest. 99, 2405-2415
36. Vreugdenhil, G.R. et al. (1999) Analysis of antibody responses against coxsackie virus B4 protein 2C and the diabetes autoantigen GAD(65). J. Med. Virol. 59, 256-261
37. Harrison, L.C. et al. (1993) Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 341, 1365-1369
38. Horwitz, M.S. et al. (1998) Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat. Med. 4, 781-785
39. Liblau, R. et al. (1997) Experimental autoimmune encephalomyelitis in IL-4-deficient mice. Int. Immunol. 9, 799-803
40. + T cells within dendritic cell clusters. Eur. J. Immunol. 33, 1686-1696
41. Schipf, A. et al. (2003) Th2 cells shape the differentiation of developing T cell responses during interactions with dendritic cells in vivo. Eur. J. Immunol. 33, 1697-1706
42. Rocken, M. et al. (1994) Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo. J. Exp. Med. 179, 1885-1893
43. Shaw, M.K. et al. (1997) Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J. Exp. Med. 185, 1711-1714
44. Broberg, E. et al. (2001) Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Ther. 8, 769-777
45. Sewell, D. et al. (2003) Immunomodulation of experimental autoimmune encephalomyelitis by helminth ova immunization. Int. Immunol. 15, 59-69
46. Tepper, R.I. et al. (1989) Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57, 503-512
47. Golumbek, P.T. et al. (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716
48. Swain, S.L. et al. (1990) IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145, 3796-3806
49. Le Gros, G. et al. (1990) Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J. Exp. Med. 172, 921-929
50. Paul, W.E. and Seder, R.A. (1994) Lymphocyte responses and cytokines. Cell 76, 241-251
51. Hochrein, H. et al. (2000) Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J. Exp. Med. 192, 823-833
52. Biedermann, T. et al. (2001) IL-4 instructs Th1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2, 1054-1060
53. Falcone, M. et al. (2001) IL-4 triggers autoimmune diabetes by increasing self-antigen presentation within the pancreatic islets. Clin. Immunol. 98, 190-199
54. + T cells, analyzed at the single-cell level. J. Exp. Med. 184, 473-483
55. Breit, S. et al. (1996) A strict requirement of interleukin-4 for interleukin-4 induction in antigen-stimulated human memory T cells. Eur. J. Immunol. 26, 1860-1865
56. Austin, L.M. et al. (1999) The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and Th1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113, 752-759
57. Ghoreschi, K. et al. (2003) Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9, 40-46
58. Menssen, A. et al. (1995) Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J. Immunol. 155, 4078-4083
59. Nicolas, J.F. et al. (1991) CD4 antibody treatment of severe psoriasis. Lancet 338, 321
60. Prinz, J. et al. (1991) Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 338, 320-321
61. Chaudhari, U. et al. (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357, 1842-1847
62. Asadullah, K. et al. (1998) IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest. 101, 783-794
63. Reich, K. et al. (1998) Treatment of psoriasis with interleukin-10. J. Invest. Dermatol. 111, 1235-1236
64. Dranoff, G. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 90, 3539-3543
65. Kalinski, P. et al. (2000) IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells. J. Immunol. 165, 1877-1881
66. Ramirez, F. and Mason, D. (2000) Induction of resistance to active experimental allergic encephalomyelitis by myelin basic protein-specific Th2 cell lines generated in the presence of glucocorticoids and IL-4. Eur. J. Immunol. 30, 747-758
67. Tisch, R. et al. (2001) A glutamic acid decarboxylase 65-specific Th2 cell clone immunoregulates autoimmune diabetes in nonobese diabetic mice. J. Immunol. 166, 6925-6936
68. + T cells producing IL-2 or IL-4. J. Immunol. 148, 1031-1036
69. Windhagen, A. et al. (1998) Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis. J. Neuroimmunol. 91, 1-9
70. Cameron, M.J. et al. (2000) Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transfer. Gene Ther. 7, 1840-1846
71. Mueller, R. et al. (1997) Mechanism underlying counterregulation of autoimmune diabetes by IL-4. Immunity 7, 411-418
72. + T cells. J. Immunol. 166, 5250-5257
73. Coon, B. et al. (1999) DNA immunization to prevent autoimmune diabetes. J. Clin. Invest. 104, 189-194
74. Wolfe, T. et al. (2002) Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: addition of IL-4 increases safety. Eur. J. Immunol. 32, 113-121
75. Garren, H. et al. (2001) Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15, 15-22
76. Tisch, R. et al. (2001) Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J. Immunol. 166, 2122-2132